-+ 0.00%
-+ 0.00%
-+ 0.00%

Missed Thyssenkrupp's Run? What Holders Had To Believe

Simply Wall St·10/10/2026 21:26:56
语音播报

If thyssenkrupp was on your watchlist instead of in your portfolio, the move since January may feel expensive in hindsight. Holding thyssenkrupp from the start of the year would have returned 42.8%, including dividends. That gain now sits alongside news of a huge Canadian submarine decision and ongoing steel restructuring. The question is simple: back on 1 January 2026, how could you have judged whether green hydrogen and green steel would really reshape this business mix?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

thyssenkrupp is not the only name tied to this theme. Zero in on 33 best rare earth metal stocks and compare how each one is priced.

What Thyssenkrupp Investors Were Really Arguing About

The shares cost €9.27 at the start of the period. The live debate was whether green hydrogen and green steel could genuinely reshape thyssenkrupp or simply add another layer of cost.

The bullish narrative pointed to a fair value of €13, based on assumptions of 4.2% annual revenue growth and profit margins rising to 4.3%, with the Marine Systems backlog and Decarbon Technologies highlighted as potential future growth engines.

The bearish view centered on a fair value of €6.3, assuming revenue would fall 0.6% a year and warning that decarbonization spending and European steel overcapacity could keep pressure on earnings.

XTRA:TKA Trailing 12-Month Earnings & Revenue History as at Oct 2026
XTRA:TKA Trailing 12-Month Earnings & Revenue History as at Oct 2026

What The Evidence Did To The Thyssenkrupp Story

Canada naming thyssenkrupp Marine Systems as preferred builder for a Patrol Submarine Project worth more than US$100b over its lifetime clearly backed the optimistic argument that defense could become a heavier profit engine. Q3 2026 results still mattered though. Revenue reached €8,786m and net income moved from a €278m loss to roughly break-even, so profitability progress remained unproven.

The practical lesson is simple. When a thesis leans on new contracts and greener products, track order backlogs, signed project values and the direction of net margin in each segment rather than only headline sales.

What Today's Thyssenkrupp Price Already Assumes

Today thyssenkrupp trades at €13.7, after a 42.8% gain from the start of the year. The selected Narrative’s Fair Value sits below the current price, reflecting concern that recent enthusiasm may already price in a lot of the hoped-for restructuring and green transformation benefits.

The same Narrative highlights heavy decarbonization costs, steel overcapacity and execution hurdles in restructuring plans as reasons for caution. The key question for anyone paying today’s price is whether thyssenkrupp can keep improving earnings while managing those legacy costs and capital demands.

"Decarbonization pressures, alternative materials, and persistent overcapacity threaten core steel demand, margins, and long-term viability against intensifying global competition. Poor restructuring execution and heavy legacy obligations restrict innovation, financial flexibility, and capacity to adapt or invest for future growth."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Which Company Could Surprise You Next?

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

  • Company 1 - 37% below our estimate - targets retail and commercial customers through expanding branches and digital channels.
  • Company 2 - 49% below our estimate - supplies steel reinforcement solutions into transportation and non-residential infrastructure construction projects.
  • Company 3 - 34% below our estimate - advances gene-editing and precision therapies for severe chronic and inherited conditions.

Three companies from the same screener. Open the full list of 173 companies trading below our estimate →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.